Trial Profile

A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in HIV-uninfected Adults at Low Risk of HIV Infection

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2024 Results assessing safety and immunogenicity of month 30 boost of ALVAC+gp120/MF59 vaccines, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
18 Apr 2019 Status changed from active, no longer recruiting to completed.
26 Jul 2017 Results assessing effects of the 12-month booster on peak post-boost and memory vaccine-induced immune responses, presented at the 9th International AIDS Society Conference on HIV Science.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com